Hospital Injectable Products · LP-196
Metoclopramide Injection
Medicine dossier. Catalogue identity is separated from unresolved product-specific fields and from external scientific references.
Development record
This dossier integrates an archived editorial source review dated 2026-09-11. Website reconciliation does not constitute a new medical or regulatory review. Controlled product approval, use instructions and supply status remain unestablished.
- Portfolio reference
- LP-196Hospital Injectable Products
- Generic identity
- MetoclopramideInjection
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Layers 01–02 · Evidence boundary
What this public record establishes — and what remains held.
- Portfolio reference
- LP-196
- Generic identity
- Metoclopramide
- Presentation
- Injection
- Catalogue strength
- 5 mg/mL
- Catalogue pack
- Ampoule 2 mL; carton 10 ampoules
- Public status
- Development presentation
Layer 01 · Controlled catalogue facts
- Generic identity: Metoclopramide.
- Dosage form: Injection.
- Catalogue strength / concentration: 5 mg/mL.
- Catalogue pack: Ampoule 2 mL; carton 10 ampoules.
- Catalogue category: Hospital Injectable Products; navigation placement is not authorisation evidence.
Layer 02 · Unresolved product-specific fields
- Sterile formulation, exact route(s), pH/osmolality and ampoule/closure specification.
- Dilution/compatibility, administration rate, renal/hepatic adjustment wording and injectable-specific monitoring.
- Approved indication, patient eligibility, dose/administration and contraindication wording for the exact product/jurisdiction.
- Storage conditions, shelf life, registration/market status, manufacturing route and current supply status.
Identity note
A current DailyMed comparator describes sterile metoclopramide injection for IV or IM administration; that route evidence is comparator-specific and cannot be transferred to LP-196.
02 · Variants
Preserve each catalogue row without inferring missing SKU relationships.
| Variant | Proposed strength / concentration | Dosage form | Presentation detail | Pack relationship | Evidence status |
|---|---|---|---|---|---|
| A | 5 mg/mL | Injection | — | Ampoule 2 mL; carton 10 ampoules | Do not infer IV/IM route, dilution or administration rate from concentration/ampoule fields alone. |
The table reproduces or structures catalogue-level fields. It does not create an approved SKU, instruction or specification where the source record does not provide one.
03 · External reference context
Ingredient and dosage-form background
Metoclopramide is a dopamine-antagonist medicine with antiemetic and gastrointestinal motility effects. Injectable formulations are used for defined indications where a parenteral route is appropriate. Its movement-disorder risk makes diagnosis, treatment duration and patient selection important. It should not be treated as a routine answer to every episode of nausea or unexplained abdominal symptoms.
Clinical context and therapeutic role
Clinical review considers the cause of nausea or vomiting, possible gastrointestinal obstruction, neurological history and alternative medicines. Different antiemetics act through different pathways and are not automatically interchangeable. Public references may describe uses that differ across jurisdictions. The catalogue provides ingredient-level education without an administration rate, dose, treatment duration or assertion that any particular external indication is authorized for this candidate.
Selected safety context
Tardive dyskinesia can be persistent and is a major concern with greater cumulative exposure. Acute dystonia, akathisia, parkinsonism, sedation and neuroleptic malignant syndrome can also occur. Review epilepsy, Parkinson disease, gastrointestinal bleeding or obstruction, depression and interacting dopamine-blocking or serotonergic medicines. New involuntary movements, severe restlessness, fever with rigidity or altered consciousness need prompt medical assessment. Kidney function may affect prescribing decisions.
Selected external context only. It is not a complete risk profile or Luang Pharma approved labelling. The exact authorised IFU/label and applicable professional guidance control product use.
Formulation, presentation and handling evidence
The source describes a 5 mg/mL injectable ampoule. Confirm salt, authorized routes, excipients and product-specific administration requirements. An oral metoclopramide leaflet does not establish injection preparation, compatibility or monitoring instructions.
Professional preparation must follow the authorized label and local aseptic procedures. Confirm the correct container, concentration, route and expiry before use. Storage, transport, dilution compatibility and any period after opening or reconstitution require product-specific evidence; this page does not establish them.
Final instructions, storage conditions, shelf life and any after-opening/in-use limits require the exact controlled product documentation; none is created from a comparator reference.
Points for professional review
Confirm the cause of symptoms, neurological and gastrointestinal contraindications, renal function, interactions and expected exposure. Use the exact authorized injectable label and local guidance.
04 · Layer 04 · Documentation gate
Controlled product documents must close the held fields.
Before this medicine record can support product-specific clinical, technical or supply claims, the exact finished-product documentation must resolve the held fields.
Finished-product specification and quantitative composition for each exact presentation.
Approved/controlled label or leaflet for the intended jurisdiction.
Controlled strength/form/pack SKU matrix and packaging artwork where more than one variant or presentation is listed.
Registration/market-status and manufacturing-site evidence for the exact presentation.
Editorial source check: archived record dated 2026-09-11.
Qualified product/medical review: Not recorded at B07d checkpoint
Approved Luang Pharma label: Not provided or established
Registration / availability / supply: not established by this public record.
05 · Layer 03 · Sources & review
External references are attributed, not adopted as Luang Pharma labelling.
| Source | Recorded revision / check | How it is used |
|---|---|---|
| MedlinePlus: Metoclopramide — ingredient/formulation referenceArchived source classification: government-hosted medicine monograph | Archived access check: 2026-09-11 | External reference; not Luang Pharma labelling, product approval, registration, equivalence, manufacturing evidence or supply evidence. |
| DailyMed: Metoclopramide injection — external label exampleArchived source classification: US official drug label example | Source revision recorded: Updated 28 April 2026; Archived access check: 2026-09-11 | External comparator for injectable route/safety context; not evidence of LP-196 route, formulation, equivalence or registration. |
External sources may describe authorised products, public-health guidance or device classes. They do not establish equivalence, approval, model performance, manufacturing status or supply eligibility for LP-196.
Professional enquiries
Request product-specific evidence for LP-196.
State the exact presentation or configuration, organisation, destination and evidence you need. The public portfolio record is not an offer of supply.